Spero Therapeutics (SPRO) Other financing activities (2018 - 2022)
Spero Therapeutics' (SPRO) quarterly Other financing activities came in at $1000.0 in Q4 2022, down 100.0% YoY from $48.5 million in Q4 2021, and down 99.57% on a QoQ basis from $231000.0 in Q2 2022.
Spero Therapeutics (SPRO) Other financing activities (2018 - 2022) Analysis & Trends
Spero Therapeutics (SPRO) has 5 years of Other financing activities data on file, last reported at $1000.0 in Q4 2022.
- Quarterly Other financing activities fell 100.0% year-over-year to $1000.0 in Q4 2022, while the trailing twelve-month figure through Sep 2023 was $1000.0 (down 100.0% YoY) and the FY2022 annual result came in at $420000.0, down 99.16% from the prior year.
- Other financing activities slipped to $1000.0 in Q4 2022, from $231000.0 in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $48.5 million in Q4 2021 to a low of $1000.0 in Q4 2022.
- A 5-year average of $3.1 million and a median of $201000.0 in 2020 frame the typical range for Other financing activities.
- Annual changes were most pronounced in 2021 — Other financing activities soared 4012.88% — and 2022, when it plunged 100.0%.
- Tracing SPRO's Other financing activities over 5 years: stood at $138000.0 in 2018, then decreased by 28.99% to $98000.0 in 2019, then jumped by 1104.08% to $1.2 million in 2020, then soared by 4012.88% to $48.5 million in 2021, then sank by 100.0% to $1000.0 in 2022.
- The last three Other financing activities figures came in at $1000.0 (Q4 2022), $231000.0 (Q2 2022), and $188000.0 (Q1 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Spero Therapeutics | 70.14 Mn | 19.37 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 1,000.00 |
| Dec 31, 2022 | 1,000.00 |
| Jun 30, 2022 | 231,000.00 |
| Jun 30, 2022 | 231,000.00 |
| Mar 31, 2022 | 188,000.00 |
| Mar 31, 2022 | 188,000.00 |
| Dec 31, 2021 | 48.53 Mn |
| Dec 31, 2021 | 48.53 Mn |
| Sep 30, 2021 | 848,000.00 |
| Sep 30, 2021 | 848,000.00 |
| Jun 30, 2021 | 277,000.00 |
| Jun 30, 2021 | 277,000.00 |
| Mar 31, 2021 | 93,000.00 |
| Mar 31, 2021 | 93,000.00 |
| Dec 31, 2020 | 1.18 Mn |
| Dec 31, 2020 | 1.18 Mn |
| Sep 30, 2020 | 201,000.00 |
| Sep 30, 2020 | 201,000.00 |
| Jun 30, 2020 | 269,000.00 |
| Jun 30, 2020 | 269,000.00 |